Cost-effectiveness of dengue vaccination in ten endemic countries

• DOI: 10.1016/j.vaccine.2017.11.064
• Publication Date: 2017-12-08T22:51:33Z
• Authors: Wu Zeng; Yara A. Halasa-Ra...; Nicolas Baurin; Laurent Coudeville; Donald S. Shepard
• Keywords: Dengue vaccine; Disability-adjusted life year

Following publication of results from two phase-3 clinical trials in 10 countries or territories, endemic began licensing the first dengue vaccine 2015. Using a published mathematical model, we evaluated cost-effectiveness vaccination populations similar to those at trial sites same Latin American and Asian countries. Our main scenarios (30-year horizon, 80% coverage) entailed 3-dose routine vaccinations costing US$20/dose beginning age 9, potentially supplemented by catch-up programs 4- 8-year cohorts. We obtained illness costs per case, mortality, wastage, administration literature. estimated that would reduce yearly direct indirect cost capita 22% (from US$10.51 US$8.17) 23% US$5.78 US$4.44) health system perspective, incremental ratio (ICER) averaged US$4,216/disability-adjusted life year (DALY) averted five (range: US$666/DALY Puerto Rico US$5,865/DALY Mexico). In countries, ICER US$3,751/DALY US$1,935/DALY Malaysia US$5,101/DALY Philippines). From proved be highly effective (ICER under one times GDP) seven 1–3 remaining three societal cost-saving Including campaigns gave ICERs. Thus, this could have favorable economic value trials.